Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announced that the ...

Shareholder/Analyst Call February 5, 2026 3:30 PM ESTCompany ParticipantsRyan Watts - Co-Founder, President, CEO ...

naturopathic medicine, functional medicine, integrative medicine, thymosin alpha-1, immunosenescence, thymic involution, inflammaging, peptide therapy ...

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need ...

JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the presentation of four ...

Qelbree-led growth, Sage acquisition synergies, and <4x forward P/S support ~25% upside into 2026. Click for more on SUPN ...

(Boston)—Alcohol use is widespread and alcohol use disorder (AUD) causes substantial harm. AUD affects 29 million individuals and causes more than 140,000 deaths annually in the U.S. alone.

Cintredekin besudotox targets IL-13 alpha-2 receptor in glioblastoma, aiming to spare healthy brain tissue while destroying cancer cells. Orphan drug designation offers benefits like lower fees and ...

First up is the successor of the venerable Cloud Alpha: the HyperX Cloud Alpha 2 – now a wireless-capable headset – features 53mm dual-chamber drivers with spatial audio support and up to 250 hours of ...

Recently these monocyte-derived alveolar macrophages, or Mo-AMs, were identified as key drivers of lung fibrosis disease progression. However, the mechanisms of their pro-fibrotic behavior and ...

A comparative study of the real-world safety and effectiveness of metronomic cyclophosphamide and bevacizumab with or without pembrolizumab for recurrent ovarian cancer. This is an ASCO Meeting ...

Narcolepsy type 1 is a disorder of hypersomnolence caused by a loss of orexin neurons, which results in low orexin levels in the brain. In this phase 2, randomized, placebo-controlled trial, ...